Phase III study of gemcitabine compared with UFT [tegafur/uracil] in patients with completely resected pathological stage IB-IIIa non small cell lung cancer.

Trial Profile

Phase III study of gemcitabine compared with UFT [tegafur/uracil] in patients with completely resected pathological stage IB-IIIa non small cell lung cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Tegafur/uracil
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 29 May 2009 New source identified and integrated (UMIN record C000000116).
    • 01 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top